Client News

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

Formycon Receives Regulatory Approval in the UK for FYB203 (Aflibercept), a Biosimilar to Eylea®, under the Brand Name AHZANTIVE®

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Mainz Biomed Expands into Switzerland with labor team w

Formycon AG Presents Clinical Data on Ustekinumab Biosimilar FYB202 at the ECCO Congress in Berlin

MIG Capital Navigates a Demanding Market Environment in 2024 and Looks Ahead to 2025 with Cautious Optimism

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

VisionHealth Announces Management Transition as Company Prepares for U.S. Launch of Kata® App

Formycon AG Informs about Recent Developments in Various Biosimilar Projects and Invites to Conference Call